Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AE, AEsAdverse event
AFAggressive fibromatosis
AHFSAmerican Hospital Formulary Service
ALTAlanine aminotransferase
AMHAnti-Mullerian hormone
ANCOVAAnalysis of covariance
aORAdjusted odds ratio
APCAdenomatous polyposis coli
APIApplication programming interface
ARRAbsolute risk reduction
ASActive surveillance
ASCOAmerican Society of Clinical Oncology
ASTAspartate aminotransferase
ASTsAdvanced solid tumors
ATActive treatment
ATUAwareness, trial and usage
AUCArea under the concentration-time curve
AUC0-infArea under the concentration-time curve from time 0 extrapolated to infinity
AUC0-tArea under the concentration-time curve from time 0 to the last observed non-zero concentration
AUCtauArea under the concentration-time curve over the dosing interval
AVAtrioventricular
AWAbdominal wall
BEBioequivalence
BICRBlinded independent central review
BIWTwice weekly
BMIBody mass index
BMSBristol-Myers Squibb
BPIBrief pain inventory
C1Cycle 1
CARClinical and radiologic
CavgAverage concentration
CBCComplete blood count
CDK4Cyclin-dependent kinase 4
CEConcept elicitation
CIConfidence interval
CmaxMaximum observed concentration
CMPComprehensive metabolic panel
COX-2Cyclooxygenase-2
CR, CRsComplete response; complete remission
CrClCreatinine clearance
CTComputed tomography
CTCAECommon Terminology Criteria for Adverse Events
CTNNB1Beta-catenin gene
CtroughConcentration before the next administration
CYP3ACytochrome P450 3A
CYP3A4Cytochrome P450 3A4
DBDouble-blind
DDIDrug-drug interaction
DEEDoxorubicin eluting embolization
DeFiDesmoid fibromatosis (phase 3 trial of nirogacestat)
DFDesmoid-type fibromatosis
DLT, DLTsDose-limiting toxicity
DORDuration of response
DT, DTsDesmoid tumor
DTFDesmoid-type fibromatosis
DTF-QoLDesmoid-Type Fibromatosis Quality of Life questionnaire
DTISDesmoid Tumor Impact Scale
DTRFDesmoid Tumor Research Foundation
DTSSDesmoid Tumor Symptom Scale
DTWGDesmoid Tumor Working Group
E-R, ERExposure-response
EAGExternal assessment group
ECG, ECGsElectrocardiogram
ECOGEastern Cooperative Oncology Group
EDTAEthylenediaminetetraacetic acid
EFSEvent-free survival
EMAEuropean Medicines Agency
EORTCEuropean Organisation for Research and Treatment of Cancer
EPAREuropean public assessment report
EQ-5DEuroQol 5-dimensional questionnaire
ESASEdmonton Symptom Assessment System
ESMOEuropean Society for Medical Oncology
EUEuropean Union
FAPFamilial adenomatous polyposis
FCTFilm-coated tablets
FDAFood and Drug Administration
FEPFederal Employee Program
FORPFemales of reproductive potential
FSHFollicle-stimulating hormone
G-BAFederal Joint Committee (Gemeinsamer Bundesausschuss)
G3, G4Grade 3, grade 4
GIGastrointestinal
GISGGerman Interdisciplinary Sarcoma Group
GISTGastrointestinal stromal tumor
GODDESSGounder/Desmoid Tumor Research Foundation Desmoid Symptom/Impact Scale
GPGeneral practitioner
GSGamma secretase
GSI, GSIsGamma secretase inhibitor
H2Histamine-2
HBHouse Bill
HES1, Hes1Hairy and enhancer of split-1
HIHepatic impairment
HIFUHigh-intensity focused ultrasound
HIVHuman immunodeficiency virus
HPNHome parenteral nutrition
HRHazard ratio
HRQL, HRQoLHealth-related quality of life
IADTsIntra-abdominal desmoid tumors
IC50sMedian inhibitory concentrations
ICD, ICD-10International Classification of Diseases; International Classification of Diseases, 10th revision
ICERIncremental cost-effectiveness ratio
ICFInformed consent form
IHCImmunohistochemistry
ILPIsolated limb perfusion
INNInternational nonproprietary name
IPInvestigational product
IQRInterquartile range
IRCCSIstituto di Ricovero e Cura a Carattere Scientifico
ISPORInternational Society for Pharmacoeconomics and Outcomes Research
ITTIntention to treat
KITKIT receptor tyrosine kinase
LFTsLiver function tests
LHLuteinizing hormone
LRFSLocal recurrence-free survival
LSLeast squares
MAAMarketing Authorization Application
MCT, MCTsMeaningful change threshold
MDM2Mouse double minute 2 homolog
MDTMultidisciplinary team
MedDRAMedical Dictionary for Regulatory Activities
MMRMMixed model for repeated measures
mRECISTModified Response Evaluation Criteria in Solid Tumors
MRIMagnetic resonance imaging
MTBMetabolite
MTDMaximum tolerated dose
MTXMethotrexate
MWAMicrowave ablation
NCANon-compartmental analysis
NCCNNational Comprehensive Cancer Network
NCODANational Community Oncology Dispensing Association
NDANew Drug Application
NDCNational Drug Code
NDRSNational Disease Registration Service
NENot estimable
NF1Neurofibromatosis type 1
NF1-PNNeurofibromatosis type 1-associated plexiform neurofibromas
NGSNext-generation sequencing
NHINational Health Insurance
NHSNational Health Service
NICENational Institute for Health and Care Excellence
NMANetwork meta-analysis
NNTNumber needed to treat
NRNot reached
NRSNumeric rating scale
NSAID, NSAIDsNonsteroidal anti-inflammatory drug
NSCLCNon-small cell lung cancer
OLEOpen-label extension
ORRObjective response rate
OSOverall survival
OTOvarian toxicity
P-gpP-glycoprotein
PAR6moProgression arrest rate at 6 months
PBOPlacebo
PDProgressive disease; pharmacodynamic
PDGFRAPlatelet-derived growth factor receptor alpha
PDUFAPrescription Drug User Fee Act
PFSProgression-free survival
PGT-MPreimplantation genetic testing for monogenic/single gene defects
Ph1, Ph2/3Phase 1; phase 2/3
PIPrincipal investigator
PKPharmacokinetics
PLDPegylated liposomal doxorubicin
POOrally
PQIPositive Quality Intervention
PR, PRsPartial response; partial remission
PRO, PROsPatient-reported outcome
PROMISPatient-Reported Outcomes Measurement Information System
PSPerformance status
ptsPatients
PV/LPVPathogenic or likely pathogenic variants
Q-TWiSTQuality-adjusted time without symptoms of disease progression or toxicity
Q2Second quarter
QALY, QALYsQuality-adjusted life year
QDOnce daily
QLQ-C30Quality of Life Questionnaire Core 30
QoLQuality of life
QTcQT interval corrected for heart rate
QTcFQT interval corrected for heart rate using Fridericia's formula
R0Microscopically negative resection margins
R1Microscopically positive resection margins
R2Macroscopically incomplete resection
rBARelative bioavailability
RECISTResponse Evaluation Criteria in Solid Tumors
RFSRecurrence-free survival
RRRisk ratio
RRePSRéseau de Référence en Pathologie des Sarcomes
RTRadiotherapy
SAEsSerious adverse events
SDStable disease; standard deviation
SEStandard error
SHIStatutory health insurance
SLDSum of longest diameter
SODSum of diameters
STSSoft tissue sarcoma
T-ALLT-cell acute lymphoblastic leukemia
t1/2Terminal elimination half-life
T2WT2-weighted
TdPTorsade de pointes
TEAE, TEAEsTreatment-emergent adverse event
TESAEsTreatment-emergent serious adverse events
TFSTreatment-free survival
TGCTTenosynovial giant cell tumor
TGITumor growth inhibition
TKI, TKIsTyrosine kinase inhibitor
TmaxTime of maximum observed plasma concentration
TNFTumor necrosis factor
TSS-5Total Symptom Score-5
TTVTotal tumor volume
TVTumor volume
UKUnited Kingdom
ULNUpper limit of normal
URELUtility of the time from disease progression until death or end of follow-up
USUnited States; ultrasound
USAUnited States of America
UTOXUtility of the time spent with treatment-related toxicity prior to disease progression
UTWiSTUtility of the time without progression or toxicity
VARVaregacestat
VBLVinblastine
vsVersus
WACWholesale acquisition cost
WHOWorld Health Organisation
WNLWithin normal limits
WNTWingless-related integration site
WPIWorst pain intensity
YAYoung adult